ATE480235T1 - Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose - Google Patents

Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose

Info

Publication number
ATE480235T1
ATE480235T1 AT02795869T AT02795869T ATE480235T1 AT E480235 T1 ATE480235 T1 AT E480235T1 AT 02795869 T AT02795869 T AT 02795869T AT 02795869 T AT02795869 T AT 02795869T AT E480235 T1 ATE480235 T1 AT E480235T1
Authority
AT
Austria
Prior art keywords
pramipexole
lateral sclerosis
amyotrophic lateral
treat amyotrophic
als
Prior art date
Application number
AT02795869T
Other languages
English (en)
Inventor
James Bennett
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of ATE480235T1 publication Critical patent/ATE480235T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Artificial Filaments (AREA)
  • Noodles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT02795869T 2001-12-11 2002-12-02 Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose ATE480235T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33938301P 2001-12-11 2001-12-11
US34737102P 2002-01-11 2002-01-11
PCT/US2002/039970 WO2003049705A2 (en) 2001-12-11 2002-12-02 Use of pramipexole to treat amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
ATE480235T1 true ATE480235T1 (de) 2010-09-15

Family

ID=26991607

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02795869T ATE480235T1 (de) 2001-12-11 2002-12-02 Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose

Country Status (20)

Country Link
US (4) US7157480B2 (de)
EP (4) EP2305253A1 (de)
JP (2) JP4500543B2 (de)
KR (1) KR20040066890A (de)
CN (1) CN1617720A (de)
AT (1) ATE480235T1 (de)
AU (1) AU2002360600B2 (de)
CA (1) CA2468747C (de)
CY (1) CY1111237T1 (de)
DE (1) DE60237635D1 (de)
DK (1) DK1453505T3 (de)
ES (2) ES2432527T3 (de)
HK (1) HK1150153A1 (de)
HU (1) HUP0500001A3 (de)
IL (1) IL162408A0 (de)
MX (1) MXPA04005572A (de)
PL (1) PL374310A1 (de)
PT (1) PT1453505E (de)
RU (1) RU2004121177A (de)
WO (1) WO2003049705A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US7157480B2 (en) * 2001-12-11 2007-01-02 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
EP1940398A1 (de) * 2005-10-18 2008-07-09 Boehringer Ingelheim International GmbH Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls)
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
EP2465500A1 (de) * 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutisch wirksame Mengen von R(+) und S(-)-Pramipexol zur Verwendung bei der Behandlung von Parkinson
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
AU2013209376B2 (en) * 2006-12-14 2016-05-05 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
JP2010513316A (ja) * 2006-12-14 2010-04-30 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソール組成物およびその使用法
AU2016210640B2 (en) * 2006-12-14 2018-02-22 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101677564A (zh) * 2007-03-14 2010-03-24 诺普神经科学股份有限公司 (6r)-4,5,6,7-四氢-n6-丙基-2,6-苯并噻唑-二胺的改良释放制剂及其使用方法
JP2010521496A (ja) * 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
GB0811642D0 (en) * 2008-06-25 2008-07-30 Univ Edinburgh Assay
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2010148409A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2014031883A1 (en) * 2012-08-23 2014-02-27 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
US10874669B2 (en) 2012-11-29 2020-12-29 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
EP2925755B1 (de) * 2012-11-29 2021-09-08 Wayne State University Neuroprotektive mittel zur behandlung von neurodegenerativen erkrankungen
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
LT3019167T (lt) 2013-07-12 2021-03-25 Knopp Biosciences Llc Eozinofilų ir (arba) bazofilų padidintų kiekių gydymas
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (de) 2013-08-13 2020-07-29 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von plasmazellenerkrankungen und prolymphozytischen b-zellen-erkrankungen
EP3681474A1 (de) 2017-09-11 2020-07-22 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Zusammensetzungen und verfahren zur nasalen verabreichung von medikamenten an das gehirn und zur systemischen wirkung

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560420A (en) 1896-05-19 Steam and oil separator
EP0186087B1 (de) * 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6043251A (en) * 1995-10-26 2000-03-28 Sanofi Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyr idine for preparing drugs for treating amyotrophic lateral sclerosis
GB9705428D0 (en) 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
AU7620600A (en) 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for cocaine craving
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
CA2415815A1 (en) * 2000-07-06 2002-01-17 Nigel H. Greig Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
US20020151526A1 (en) * 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US7157480B2 (en) * 2001-12-11 2007-01-02 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
CN102772357B (zh) * 2003-03-31 2014-12-31 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復

Also Published As

Publication number Publication date
EP1453505A2 (de) 2004-09-08
EP1453505B1 (de) 2010-09-08
HK1150153A1 (en) 2011-11-04
JP2005516911A (ja) 2005-06-09
EP1453505A4 (de) 2007-01-10
HUP0500001A2 (hu) 2005-04-28
US20130172394A1 (en) 2013-07-04
ES2432527T3 (es) 2013-12-04
WO2003049705A2 (en) 2003-06-19
EP2305253A1 (de) 2011-04-06
HUP0500001A3 (en) 2005-11-28
CY1111237T1 (el) 2015-06-11
PT1453505E (pt) 2010-12-16
AU2002360600B2 (en) 2007-11-29
JP4500543B2 (ja) 2010-07-14
US20110301210A1 (en) 2011-12-08
KR20040066890A (ko) 2004-07-27
EP2246053A1 (de) 2010-11-03
US7157480B2 (en) 2007-01-02
CA2468747C (en) 2011-05-31
EP2305252A1 (de) 2011-04-06
JP2010031059A (ja) 2010-02-12
US20050032856A1 (en) 2005-02-10
CN1617720A (zh) 2005-05-18
RU2004121177A (ru) 2005-03-10
MXPA04005572A (es) 2004-12-06
CA2468747A1 (en) 2003-06-19
AU2002360600A1 (en) 2003-06-23
EP2246053B1 (de) 2013-09-18
PL374310A1 (en) 2005-10-03
ES2351303T3 (es) 2011-02-02
DK1453505T3 (da) 2010-11-15
DE60237635D1 (de) 2010-10-21
IL162408A0 (en) 2005-11-20
US20070105918A1 (en) 2007-05-10
WO2003049705A3 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
ATE480235T1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
ATE544449T1 (de) Neue verwendung von peptidverbindungen zur behandlung von amyothropher lateralsklerose
DE60219917D1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
ATE353880T1 (de) Neue verwendung von pyrimidin- oder triazin-2- carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2- carbonsäurenitrilderivate
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
DE60116313D1 (de) Verbindungen zur behandlung der alzheimerischen krankheit
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60210093D1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
WO2002002520A3 (en) Compounds to treat alzheimer's disease
DE122012000007I1 (de) Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung.
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
DE69805672D1 (de) Verwendung von Rifaximin als Medikament zur Behandlung von durch Cryptosporidiose verursachten Diarrhoeen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE333451T1 (de) Verwendung von nitrilenverbindungen als arztneimittel
MY139368A (en) Novel cyclohexyl sulphones
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE287713T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE360425T1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1453505

Country of ref document: EP